These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23654144)

  • 41. Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment.
    Marcellin P; Craxi A; Brandao-Mello CE; Di Bisceglie AM; Andreone P; Freilich B; Rajender Reddy K; Olveira Martín A; Teuber G; Messinger D; Hooper G; Wat C; Tatsch F; Jensen DM
    J Clin Gastroenterol; 2013 Oct; 47(9):786-93. PubMed ID: 23442834
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.
    Rossignol JF; Elfert A; El-Gohary Y; Keeffe EB
    Gastroenterology; 2009 Mar; 136(3):856-62. PubMed ID: 19135998
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of the efficacy of ribavirin plus peginterferon alfa-2b for chronic hepatitis C infection in patients with and without coagulation disorders.
    Honda T; Katano Y; Kuzuya T; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Ishikawa T; Toyoda H; Kumada T; Yamamoto K; Matsushita T; Kojima T; Takamatsu J; Goto H
    J Med Virol; 2013 Feb; 85(2):228-34. PubMed ID: 23160930
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
    Ascione A; De Luca M; Tartaglione MT; Lampasi F; Di Costanzo GG; Lanza AG; Picciotto FP; Marino-Marsilia G; Fontanella L; Leandro G
    Gastroenterology; 2010 Jan; 138(1):116-22. PubMed ID: 19852964
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The study of relationship between neutropenia and infection during treatment with peginterferon α and ribavirin for chronic hepatitis C.
    Yu JW; Sun LJ; Zhao YH; Kang P; Yan BZ
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1192-9. PubMed ID: 21971375
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.
    Hassanein T; Cooksley G; Sulkowski M; Smith C; Marinos G; Lai MY; Pastore G; Trejo-Estrada R; Horta E Vale A; Wintfeld N; Green J
    J Hepatol; 2004 Apr; 40(4):675-81. PubMed ID: 15030985
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interstitial pneumonia recurrence during chronic hepatitis C treatment.
    Renou C; Germain S; Harafa A; Martin S; Larroque O; Muller P; Bertrand JJ; Halfon P
    Am J Gastroenterol; 2005 Jul; 100(7):1625-6. PubMed ID: 15984999
    [No Abstract]   [Full Text] [Related]  

  • 49. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.
    Rumi MG; Aghemo A; Prati GM; D'Ambrosio R; Donato MF; Soffredini R; Del Ninno E; Russo A; Colombo M
    Gastroenterology; 2010 Jan; 138(1):108-15. PubMed ID: 19766645
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin.
    Onyike CU; Bonner JO; Lyketsos CG; Treisman GJ
    Am J Psychiatry; 2004 Mar; 161(3):429-35. PubMed ID: 14992966
    [No Abstract]   [Full Text] [Related]  

  • 51. Tubo-ovarian abscess during therapy of chronic hepatitis C with pegylated interferon and ribavirin.
    Inglot M; Szymczak A; Fleischer-Stepniewska K; Fleischer M; Staszek-Zurowska B; Gladysz A
    Neuro Endocrinol Lett; 2011; 32(1):1-3. PubMed ID: 21407153
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Autoimmune hemolytic anemia in a case of chronic hepatitis type C 56 weeks after initiation of second line treatment with pegylated interferon alpha2b/ribavirin combination therapy].
    Nishino R; Ikeda N; Unoura M
    Nihon Shokakibyo Gakkai Zasshi; 2011 Sep; 108(9):1571-8. PubMed ID: 21891998
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea].
    Lee H; Choi MS; Paik SW; Kim JH; Kim DY; Lee JH; Koh KC; Yoo BC; Rhee JC; Song SM
    Korean J Hepatol; 2006 Mar; 12(1):31-40. PubMed ID: 16565604
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Pulmonary toxicity by pegylated interferon alpha-2a in a patient with chronic hepatitis C].
    Son BK; Sohn JH; Kim TY; Park YK; Jeon YC; Han DS
    Korean J Hepatol; 2007 Mar; 13(1):103-7. PubMed ID: 17380081
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients.
    Lawitz E; Rodriguez-Torres M; Muir AJ; Kieffer TL; McNair L; Khunvichai A; McHutchison JG
    J Hepatol; 2008 Aug; 49(2):163-9. PubMed ID: 18486984
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Side effects of therapy for chronic hepatitis C.
    Russo MW; Fried MW
    Gastroenterology; 2003 May; 124(6):1711-9. PubMed ID: 12761728
    [No Abstract]   [Full Text] [Related]  

  • 57. [Side effect of pegylated-interferon treatment in chronic C hepatitis: agranulocytosis].
    Halász T; Farkas A; Tolvaj G; Horváth G
    Orv Hetil; 2006 Feb; 147(7):321-4. PubMed ID: 17489160
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Pegylated interferon alfa-2a. Improved prognosis in hepatitis C].
    MMW Fortschr Med; 2002 Sep; 144(38):59. PubMed ID: 12395712
    [No Abstract]   [Full Text] [Related]  

  • 59. Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial.
    Shoeb D; Dearden J; Weatherall A; Bargery C; Moreea S; Alam S; White E; Vila X; Freshwater D; Ryder S; Mills PR; Alexander GJ; Forton D; Foster GR
    J Hepatol; 2014 Apr; 60(4):699-705. PubMed ID: 24291239
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cutaneous reactions in patients with chronic hepatitis C treated with peginterferon and ribavirin.
    Patrk I; Morović M; Markulin A; Patrk J
    Dermatology; 2014; 228(1):42-6. PubMed ID: 24434490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.